+Compare
PRTA
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
3.67B

PRTA Price Prediction, Prothena Corp AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for PRTA with price predictions
08:00 PM EDT Jun 08, 2023

PRTA sees MACD Histogram crosses below signal line

PRTA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on May 22, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PRTA moved out of overbought territory on May 18, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where PRTA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 07, 2023. You may want to consider a long position or call options on PRTA as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PRTA advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

PRTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 192 cases where PRTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PRTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.035) is normal, around the industry mean (25.340). P/E Ratio (21.882) is within average values for comparable stocks, (123.530). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.381). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (61.728) is also within normal values, averaging (310.379).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

A.I. Advisor
published Earnings

PRTA is expected to report earnings to rise 7.82% to -95 cents per share on August 08

Prothena Corp PRTA Stock Earnings Reports
Q2'23
Est.
$-0.96
Q1'23
Missed
by $0.02
Q4'22
Beat
by $0.59
Q3'22
Missed
by $0.38
Q2'22
Missed
by $0.36
The last earnings report on May 04 showed earnings per share of -88 cents, missing the estimate of -87 cents. With 281.00K shares outstanding, the current market capitalization sits at 3.67B.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.14B. The market cap for tickers in the group ranges from 402 to 354.23B. NONOF holds the highest valuation in this group at 354.23B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 36%. ONPH experienced the highest price growth at 129%, while BLPH experienced the biggest fall at -90%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 55
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel antibodies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
77 Sir John Rogerson’s Quay
Phone
+353 12362500
Employees
127
Web
https://www.prothena.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CWEB39.160.22
+0.56%
Direxion Dly CSI CHN Itnet Bull 2X Shrs
AIA60.840.17
+0.28%
iShares Asia 50 ETF
AAPD21.67-0.03
-0.15%
Direxion Daily AAPL Bear 1X Shares
DEW46.78-0.08
-0.17%
WisdomTree Global High Dividend ETF
NKEL23.62-0.09
-0.38%
AXS 2X NKE Bull Daily ETF

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with ABOS. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
-0.64%
ABOS - PRTA
59%
Loosely correlated
-0.41%
DNLI - PRTA
55%
Loosely correlated
-1.77%
ARWR - PRTA
51%
Loosely correlated
-1.06%
PEPG - PRTA
50%
Loosely correlated
-25.08%
ALEC - PRTA
49%
Loosely correlated
-0.95%
More